Global Nanoparticle Mediated Delivery Market

Nanoparticle Mediated Delivery Comprehensive Study by Type (Organic Nanoparticles (A,B), Inorganic Nanoparticles (C–G), Hybrid Nanoparticles), Application (Hospitals, Laboratories, Biopharmaceutical Research Institutes), Therapeutic Agents (Exosomes, Cells, Engineered Tissues, Small Molecules), Delivery (Drug Delivery, Gene Delivery) Players and Region - Global Market Outlook to 2030

Nanoparticle Mediated Delivery Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 15.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Nanoparticle Mediated Delivery Market Scope
Nanoparticle mediated delivery provides drug carriers with high stability, high capacity, the feasibility of different substances for various routes of administration. It is used in hospitals, biopharmaceutical research institutes, and laboratories, there are organic nanoparticles, inorganic nanoparticles, and hybrid nanoparticles which are used in drug or gene delivery. These nanoparticle mediated delivery have abilities to increase the water solubility and stability of drugs, reduce enzyme degradation, and improves the effectiveness and safety of drugs.

According to AMA, the Global Nanoparticle Mediated Delivery market is expected to see growth rate of 15.6%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Nanoparticle Mediated Delivery market throughout the predicted period.

AbbVie (United States), Cristal Therapeutics (Netherlands), EnColl Corporation (United States), Nanobiotix (France), Nanospectra Biosciences Inc (United States) and Selecta Biosciences (United States) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Nanoparticle Mediated Delivery market by Type (Organic Nanoparticles (A,B), Inorganic Nanoparticles (C–G) and Hybrid Nanoparticles), by Application (Hospitals, Laboratories and Biopharmaceutical Research Institutes) and Region with country level break-up.

On the basis of geography, the market of Nanoparticle Mediated Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Advancement in Plant Genetic Engineering for Nanoparticle Mediated Delivery

Market Growth Drivers:
Rising Cardiovascular Diseases in Young Population And Need for Treatment and Medication Delivery and Demand for the Drug Carriers with High Stability, High Capacity, and Feasibility of Incorporation

Challenges:
Delivery Systems related Uncertain Problem in Nanoparticle Mediated Delivery

Restraints:
Stringent Regulatory Guidelines and Standards Associated with Nanoparticle Mediated Delivery

Opportunities:
Continuous Research and Development in the Nanoparticle Mediated Delivery Sytems and Rising Diagnosis of Cardiovascular Diseases will Boost the Nanoparticle Mediated Delivery Market

Market Leaders and their Expansionary Development Strategies
In November , 2023 AbbVie Inc.and ImmunoGen, Inc. announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
In February 2021, Selecta Biosciences, Inc. a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, announced the peer-reviewed publication of a study investigating the effects of the co-administration of ImmTOR nanoparticles to adeno-associated viral (AAV) vectors on transgene expression in mice.


Key Target Audience
Nanoparticle Mediated Delivery Providers, Nanoparticle Mediated Delivery Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Organic Nanoparticles (A,B)
  • Inorganic Nanoparticles (C–G)
  • Hybrid Nanoparticles
By Application
  • Hospitals
  • Laboratories
  • Biopharmaceutical Research Institutes
By Therapeutic Agents
  • Exosomes
  • Cells
  • Engineered Tissues
  • Small Molecules

By Delivery
  • Drug Delivery
  • Gene Delivery

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Cardiovascular Diseases in Young Population And Need for Treatment and Medication Delivery
      • 3.2.2. Demand for the Drug Carriers with High Stability, High Capacity, and Feasibility of Incorporation
    • 3.3. Market Challenges
      • 3.3.1. Delivery Systems related Uncertain Problem in Nanoparticle Mediated Delivery
    • 3.4. Market Trends
      • 3.4.1. Advancement in Plant Genetic Engineering for Nanoparticle Mediated Delivery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nanoparticle Mediated Delivery, by Type, Application, Therapeutic Agents, Delivery and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nanoparticle Mediated Delivery (Value)
      • 5.2.1. Global Nanoparticle Mediated Delivery by: Type (Value)
        • 5.2.1.1. Organic Nanoparticles (A,B)
        • 5.2.1.2. Inorganic Nanoparticles (C–G)
        • 5.2.1.3. Hybrid Nanoparticles
      • 5.2.2. Global Nanoparticle Mediated Delivery by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Laboratories
        • 5.2.2.3. Biopharmaceutical Research Institutes
      • 5.2.3. Global Nanoparticle Mediated Delivery by: Therapeutic Agents (Value)
        • 5.2.3.1. Exosomes
        • 5.2.3.2. Cells
        • 5.2.3.3. Engineered Tissues
        • 5.2.3.4. Small Molecules
      • 5.2.4. Global Nanoparticle Mediated Delivery by: Delivery (Value)
        • 5.2.4.1. Drug Delivery
        • 5.2.4.2. Gene Delivery
      • 5.2.5. Global Nanoparticle Mediated Delivery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Nanoparticle Mediated Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cristal Therapeutics (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. EnColl Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nanobiotix (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nanospectra Biosciences Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Selecta Biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Nanoparticle Mediated Delivery Sale, by Type, Application, Therapeutic Agents, Delivery and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nanoparticle Mediated Delivery (Value)
      • 7.2.1. Global Nanoparticle Mediated Delivery by: Type (Value)
        • 7.2.1.1. Organic Nanoparticles (A,B)
        • 7.2.1.2. Inorganic Nanoparticles (C–G)
        • 7.2.1.3. Hybrid Nanoparticles
      • 7.2.2. Global Nanoparticle Mediated Delivery by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Laboratories
        • 7.2.2.3. Biopharmaceutical Research Institutes
      • 7.2.3. Global Nanoparticle Mediated Delivery by: Therapeutic Agents (Value)
        • 7.2.3.1. Exosomes
        • 7.2.3.2. Cells
        • 7.2.3.3. Engineered Tissues
        • 7.2.3.4. Small Molecules
      • 7.2.4. Global Nanoparticle Mediated Delivery by: Delivery (Value)
        • 7.2.4.1. Drug Delivery
        • 7.2.4.2. Gene Delivery
      • 7.2.5. Global Nanoparticle Mediated Delivery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nanoparticle Mediated Delivery: by Type(USD Million)
  • Table 2. Nanoparticle Mediated Delivery Organic Nanoparticles (A,B) , by Region USD Million (2018-2023)
  • Table 3. Nanoparticle Mediated Delivery Inorganic Nanoparticles (C–G) , by Region USD Million (2018-2023)
  • Table 4. Nanoparticle Mediated Delivery Hybrid Nanoparticles , by Region USD Million (2018-2023)
  • Table 5. Nanoparticle Mediated Delivery: by Application(USD Million)
  • Table 6. Nanoparticle Mediated Delivery Hospitals , by Region USD Million (2018-2023)
  • Table 7. Nanoparticle Mediated Delivery Laboratories , by Region USD Million (2018-2023)
  • Table 8. Nanoparticle Mediated Delivery Biopharmaceutical Research Institutes , by Region USD Million (2018-2023)
  • Table 9. Nanoparticle Mediated Delivery: by Therapeutic Agents(USD Million)
  • Table 10. Nanoparticle Mediated Delivery Exosomes , by Region USD Million (2018-2023)
  • Table 11. Nanoparticle Mediated Delivery Cells , by Region USD Million (2018-2023)
  • Table 12. Nanoparticle Mediated Delivery Engineered Tissues , by Region USD Million (2018-2023)
  • Table 13. Nanoparticle Mediated Delivery Small Molecules , by Region USD Million (2018-2023)
  • Table 14. Nanoparticle Mediated Delivery: by Delivery(USD Million)
  • Table 15. Nanoparticle Mediated Delivery Drug Delivery , by Region USD Million (2018-2023)
  • Table 16. Nanoparticle Mediated Delivery Gene Delivery , by Region USD Million (2018-2023)
  • Table 17. South America Nanoparticle Mediated Delivery, by Country USD Million (2018-2023)
  • Table 18. South America Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 19. South America Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 20. South America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 21. South America Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 22. Brazil Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 23. Brazil Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 24. Brazil Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 25. Brazil Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 26. Argentina Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 27. Argentina Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 28. Argentina Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 29. Argentina Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 30. Rest of South America Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 33. Rest of South America Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 34. Asia Pacific Nanoparticle Mediated Delivery, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 38. Asia Pacific Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 39. China Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 40. China Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 41. China Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 42. China Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 43. Japan Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 44. Japan Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 45. Japan Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 46. Japan Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 47. India Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 48. India Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 49. India Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 50. India Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 51. South Korea Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 52. South Korea Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 53. South Korea Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 54. South Korea Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 55. Taiwan Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 56. Taiwan Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 57. Taiwan Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 58. Taiwan Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 59. Australia Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 60. Australia Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 61. Australia Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 62. Australia Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 67. Europe Nanoparticle Mediated Delivery, by Country USD Million (2018-2023)
  • Table 68. Europe Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 69. Europe Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 70. Europe Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 71. Europe Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 72. Germany Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 73. Germany Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 74. Germany Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 75. Germany Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 76. France Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 77. France Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 78. France Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 79. France Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 80. Italy Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 81. Italy Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 82. Italy Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 83. Italy Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 84. United Kingdom Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 87. United Kingdom Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 88. Netherlands Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 89. Netherlands Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 90. Netherlands Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 91. Netherlands Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 92. Rest of Europe Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 95. Rest of Europe Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 96. MEA Nanoparticle Mediated Delivery, by Country USD Million (2018-2023)
  • Table 97. MEA Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 98. MEA Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 99. MEA Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 100. MEA Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 101. Middle East Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 102. Middle East Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 103. Middle East Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 104. Middle East Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 105. Africa Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 106. Africa Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 107. Africa Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 108. Africa Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 109. North America Nanoparticle Mediated Delivery, by Country USD Million (2018-2023)
  • Table 110. North America Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 111. North America Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 112. North America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 113. North America Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 114. United States Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 115. United States Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 116. United States Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 117. United States Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 118. Canada Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 119. Canada Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 120. Canada Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 121. Canada Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 122. Mexico Nanoparticle Mediated Delivery, by Type USD Million (2018-2023)
  • Table 123. Mexico Nanoparticle Mediated Delivery, by Application USD Million (2018-2023)
  • Table 124. Mexico Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2018-2023)
  • Table 125. Mexico Nanoparticle Mediated Delivery, by Delivery USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Nanoparticle Mediated Delivery: by Type(USD Million)
  • Table 133. Nanoparticle Mediated Delivery Organic Nanoparticles (A,B) , by Region USD Million (2025-2030)
  • Table 134. Nanoparticle Mediated Delivery Inorganic Nanoparticles (C–G) , by Region USD Million (2025-2030)
  • Table 135. Nanoparticle Mediated Delivery Hybrid Nanoparticles , by Region USD Million (2025-2030)
  • Table 136. Nanoparticle Mediated Delivery: by Application(USD Million)
  • Table 137. Nanoparticle Mediated Delivery Hospitals , by Region USD Million (2025-2030)
  • Table 138. Nanoparticle Mediated Delivery Laboratories , by Region USD Million (2025-2030)
  • Table 139. Nanoparticle Mediated Delivery Biopharmaceutical Research Institutes , by Region USD Million (2025-2030)
  • Table 140. Nanoparticle Mediated Delivery: by Therapeutic Agents(USD Million)
  • Table 141. Nanoparticle Mediated Delivery Exosomes , by Region USD Million (2025-2030)
  • Table 142. Nanoparticle Mediated Delivery Cells , by Region USD Million (2025-2030)
  • Table 143. Nanoparticle Mediated Delivery Engineered Tissues , by Region USD Million (2025-2030)
  • Table 144. Nanoparticle Mediated Delivery Small Molecules , by Region USD Million (2025-2030)
  • Table 145. Nanoparticle Mediated Delivery: by Delivery(USD Million)
  • Table 146. Nanoparticle Mediated Delivery Drug Delivery , by Region USD Million (2025-2030)
  • Table 147. Nanoparticle Mediated Delivery Gene Delivery , by Region USD Million (2025-2030)
  • Table 148. South America Nanoparticle Mediated Delivery, by Country USD Million (2025-2030)
  • Table 149. South America Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 150. South America Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 151. South America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 152. South America Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 153. Brazil Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 154. Brazil Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 155. Brazil Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 156. Brazil Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 157. Argentina Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 158. Argentina Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 159. Argentina Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 160. Argentina Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 161. Rest of South America Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 162. Rest of South America Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 163. Rest of South America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 164. Rest of South America Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 165. Asia Pacific Nanoparticle Mediated Delivery, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 167. Asia Pacific Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 168. Asia Pacific Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 169. Asia Pacific Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 170. China Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 171. China Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 172. China Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 173. China Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 174. Japan Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 175. Japan Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 176. Japan Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 177. Japan Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 178. India Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 179. India Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 180. India Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 181. India Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 182. South Korea Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 183. South Korea Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 184. South Korea Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 185. South Korea Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 186. Taiwan Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 187. Taiwan Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 188. Taiwan Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 189. Taiwan Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 190. Australia Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 191. Australia Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 192. Australia Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 193. Australia Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 198. Europe Nanoparticle Mediated Delivery, by Country USD Million (2025-2030)
  • Table 199. Europe Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 200. Europe Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 201. Europe Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 202. Europe Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 203. Germany Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 204. Germany Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 205. Germany Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 206. Germany Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 207. France Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 208. France Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 209. France Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 210. France Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 211. Italy Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 212. Italy Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 213. Italy Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 214. Italy Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 215. United Kingdom Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 216. United Kingdom Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 217. United Kingdom Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 218. United Kingdom Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 219. Netherlands Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 220. Netherlands Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 221. Netherlands Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 222. Netherlands Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 223. Rest of Europe Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 224. Rest of Europe Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 225. Rest of Europe Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 226. Rest of Europe Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 227. MEA Nanoparticle Mediated Delivery, by Country USD Million (2025-2030)
  • Table 228. MEA Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 229. MEA Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 230. MEA Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 231. MEA Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 232. Middle East Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 233. Middle East Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 234. Middle East Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 235. Middle East Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 236. Africa Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 237. Africa Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 238. Africa Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 239. Africa Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 240. North America Nanoparticle Mediated Delivery, by Country USD Million (2025-2030)
  • Table 241. North America Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 242. North America Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 243. North America Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 244. North America Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 245. United States Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 246. United States Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 247. United States Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 248. United States Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 249. Canada Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 250. Canada Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 251. Canada Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 252. Canada Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 253. Mexico Nanoparticle Mediated Delivery, by Type USD Million (2025-2030)
  • Table 254. Mexico Nanoparticle Mediated Delivery, by Application USD Million (2025-2030)
  • Table 255. Mexico Nanoparticle Mediated Delivery, by Therapeutic Agents USD Million (2025-2030)
  • Table 256. Mexico Nanoparticle Mediated Delivery, by Delivery USD Million (2025-2030)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nanoparticle Mediated Delivery: by Type USD Million (2018-2023)
  • Figure 5. Global Nanoparticle Mediated Delivery: by Application USD Million (2018-2023)
  • Figure 6. Global Nanoparticle Mediated Delivery: by Therapeutic Agents USD Million (2018-2023)
  • Figure 7. Global Nanoparticle Mediated Delivery: by Delivery USD Million (2018-2023)
  • Figure 8. South America Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 9. Asia Pacific Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 10. Europe Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 11. MEA Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 12. North America Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 13. Global Nanoparticle Mediated Delivery share by Players 2023 (%)
  • Figure 14. Global Nanoparticle Mediated Delivery share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 17. AbbVie (United States) Revenue: by Geography 2023
  • Figure 18. Cristal Therapeutics (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Cristal Therapeutics (Netherlands) Revenue: by Geography 2023
  • Figure 20. EnColl Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. EnColl Corporation (United States) Revenue: by Geography 2023
  • Figure 22. Nanobiotix (France) Revenue, Net Income and Gross profit
  • Figure 23. Nanobiotix (France) Revenue: by Geography 2023
  • Figure 24. Nanospectra Biosciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Nanospectra Biosciences Inc (United States) Revenue: by Geography 2023
  • Figure 26. Selecta Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Selecta Biosciences (United States) Revenue: by Geography 2023
  • Figure 28. Global Nanoparticle Mediated Delivery: by Type USD Million (2025-2030)
  • Figure 29. Global Nanoparticle Mediated Delivery: by Application USD Million (2025-2030)
  • Figure 30. Global Nanoparticle Mediated Delivery: by Therapeutic Agents USD Million (2025-2030)
  • Figure 31. Global Nanoparticle Mediated Delivery: by Delivery USD Million (2025-2030)
  • Figure 32. South America Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 33. Asia Pacific Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 34. Europe Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 35. MEA Nanoparticle Mediated Delivery Share (%), by Country
  • Figure 36. North America Nanoparticle Mediated Delivery Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Cristal Therapeutics (Netherlands)
  • EnColl Corporation (United States)
  • Nanobiotix (France)
  • Nanospectra Biosciences Inc (United States)
  • Selecta Biosciences (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 222 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nanoparticle Mediated Delivery Market Quantitative research analysis
Global Nanoparticle Mediated Delivery Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Nanoparticle Mediated Delivery study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Nanoparticle Mediated Delivery Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Nanoparticle Mediated Delivery market is expected to see growth rate of xx%.
The Nanoparticle Mediated Delivery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Nanoparticle Mediated Delivery Market Report?

Have a Query? Click Here

Other Related Reports

Elective Healthcare Services Comprehensive Study by Type (Medical And Diagnostic Laboratory Services, Dental Services, Ambulatory Health Care Services, Residential Nursing Care Services, Others), App...
$ 3650
Gallbladder Treatment Comprehensive Study by Treatment (Surgical (Immunotherapy, Chemotherapy, Radiation Therapy), Non-Surgical (Medication)), End Use (Hospitals, Gynecology Clinics), Stage (Stage I,...
$ 3650
Rib Fracture Repair Systems Comprehensive Study by Type (U Plate Rib Fracture Repair Systems, Anterior Plate Rib Fracture Repair Systems), Application (Hospitals, Ambulatory Surgical Centers, Special...
$ 3500
Quantitative Transcriptome Analysis Comprehensive Study by Type (Medical Instruments, Consumables, Services), Application (Drug Discovery and Development, Cancer Research, Diagnosis, Disease Treatmen...
$ 3750
Dental Microsurgery Comprehensive Study by Type (Endodontic Procedures, Periodontal Procedures, Dental Implants, Apicoectomy, Others), Application (General Surgery, Neurosurgery, Ophthalmology, Recon...
$ 3650
Pharmaceutical Locker Comprehensive Study by Type (Staff Lockers, Shipment Lockers), Distribution Channels (Direct Sales, Indirect Sales), Pharma Factory (Hospital, Pharmacy, Clinic, Other), Lock (Di...
$ 3500